<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Nivolumab - Wikipedia</title>
<script>document.documentElement.className = document.documentElement.className.replace( /(^|\s)client-nojs(\s|$)/, "$1client-js$2" );</script>
<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Nivolumab","wgTitle":"Nivolumab","wgCurRevisionId":880151338,"wgRevisionId":880151338,"wgArticleId":35007537,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Chemicals that do not have a ChemSpider ID assigned","Articles without EBI source","Chemical pages without DrugBank identifier","Articles without InChI source","Articles without UNII source","Drugs with no legal status","Drug has EMA link","Articles containing unverified chemical infoboxes","Drugs that are a monoclonal antibody","Bristol-Myers Squibb","Monoclonal antibodies","Antineoplastic drugs","Breakthrough therapy","Monoclonal antibodies for tumors"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Nivolumab","wgRelevantArticleId":35007537,"wgRequestId":"XE4QgQpAMFAAAB-ux3cAAAAY","wgCSPNonce":false,"wgIsProbablyEditable":true,"wgRelevantPageIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgFlaggedRevsParams":{"tags":{}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgWikiEditorEnabledModules":[],"wgBetaFeaturesFeatures":[],"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgPopupsShouldSendModuleToUser":true,"wgPopupsConflictsWithNavPopupGadget":false,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en","usePageImages":true,"usePageDescriptions":true},"wgMFExpandAllSectionsUserOption":true,"wgMFEnableFontChanger":true,"wgMFDisplayWikibaseDescriptions":{"search":true,"nearby":true,"watchlist":true,"tagline":false},"wgRelatedArticles":null,"wgRelatedArticlesUseCirrusSearch":true,"wgRelatedArticlesOnlyUseCirrusSearch":false,"wgWMESchemaEditAttemptStepOversample":false,"wgPoweredByHHVM":true,"wgULSCurrentAutonym":"English","wgNoticeProject":"wikipedia","wgCentralNoticeCookiesToDelete":[],"wgCentralNoticeCategoriesUsingLegacy":["Fundraising","fundraising"],"wgWikibaseItemId":"Q7041828","wgScoreNoteLanguages":{"arabic":"العربية","catalan":"català","deutsch":"Deutsch","english":"English","espanol":"español","italiano":"italiano","nederlands":"Nederlands","norsk":"norsk","portugues":"português","suomi":"suomi","svenska":"svenska","vlaams":"West-Vlams"},"wgScoreDefaultNoteLanguage":"nederlands","wgCentralAuthMobileDomain":false,"wgCodeMirrorEnabled":true,"wgVisualEditorToolbarScrollOffset":0,"wgVisualEditorUnsupportedEditParams":["undo","undoafter","veswitched"],"wgEditSubmitButtonLabelPublish":true,"oresWikiId":"enwiki","oresBaseUrl":"http://ores.discovery.wmnet:8081/","oresApiVersion":3});mw.loader.state({"ext.gadget.charinsert-styles":"ready","ext.globalCssJs.user.styles":"ready","ext.globalCssJs.site.styles":"ready","site.styles":"ready","noscript":"ready","user.styles":"ready","ext.globalCssJs.user":"ready","ext.globalCssJs.site":"ready","user":"ready","user.options":"ready","user.tokens":"loading","ext.cite.styles":"ready","mediawiki.legacy.shared":"ready","mediawiki.legacy.commonPrint":"ready","mediawiki.toc.styles":"ready","wikibase.client.init":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.uls.interlanguage":"ready","ext.wikimediaBadges":"ready","ext.3d.styles":"ready","mediawiki.skinning.interface":"ready","skins.vector.styles":"ready"});mw.loader.implement("user.tokens@0tffind",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});RLPAGEMODULES=["ext.cite.ux-enhancements","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","mediawiki.searchSuggest","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.watchlist-notice","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.extra-toolbar-buttons","ext.gadget.switcher","ext.centralauth.centralautologin","mmv.head","mmv.bootstrap.autostart","ext.popups","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","ext.uls.eventlogger","ext.uls.init","ext.uls.compactlinks","ext.uls.interface","ext.quicksurveys.init","ext.centralNotice.geoIP","ext.centralNotice.startUp","skins.vector.js"];mw.loader.load(RLPAGEMODULES);});</script>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=ext.3d.styles%7Cext.cite.styles%7Cext.uls.interlanguage%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediaBadges%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.skinning.interface%7Cmediawiki.toc.styles%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector"/>
<script async="" src="/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector"></script>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=ext.gadget.charinsert-styles&amp;only=styles&amp;skin=vector"/>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=vector"/>
<meta name="generator" content="MediaWiki 1.33.0-wmf.14"/>
<meta name="referrer" content="origin"/>
<meta name="referrer" content="origin-when-crossorigin"/>
<meta name="referrer" content="origin-when-cross-origin"/>
<meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Nivolumab_5GGR.png/1200px-Nivolumab_5GGR.png"/>
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Nivolumab"/>
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Nivolumab&amp;action=edit"/>
<link rel="edit" title="Edit this page" href="/w/index.php?title=Nivolumab&amp;action=edit"/>
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"/>
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"/>
<link rel="license" href="//creativecommons.org/licenses/by-sa/3.0/"/>
<link rel="canonical" href="https://en.wikipedia.org/wiki/Nivolumab"/>
<link rel="dns-prefetch" href="//login.wikimedia.org"/>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 9]><script src="/w/load.php?debug=false&amp;lang=en&amp;modules=html5shiv&amp;only=scripts&amp;skin=vector&amp;sync=1"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Nivolumab rootpage-Nivolumab skin-vector action-view">		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>
			<div id="siteNotice" class="mw-body-content"><!-- CentralNotice --></div><div class="mw-indicators mw-body-content">
</div>
<h1 id="firstHeading" class="firstHeading" lang="en">Nivolumab</h1>			<div id="bodyContent" class="mw-body-content">
				<div id="siteSub" class="noprint">From Wikipedia, the free encyclopedia</div>				<div id="contentSub"></div>
				<div id="jump-to-nav"></div>				<a class="mw-jump-link" href="#mw-head">Jump to navigation</a>
				<a class="mw-jump-link" href="#p-search">Jump to search</a>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><table class="infobox" style="width:22em;border-spacing:2px;"><caption><span title="International nonproprietary name (INN): Nivolumab">Nivolumab</span></caption><tbody><tr><td colspan="2" style="text-align:center"><a href="/wiki/File:Nivolumab_5GGR.png" class="image"><img alt="Nivolumab 5GGR.png" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Nivolumab_5GGR.png/220px-Nivolumab_5GGR.png" decoding="async" width="220" height="253" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Nivolumab_5GGR.png/330px-Nivolumab_5GGR.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Nivolumab_5GGR.png/440px-Nivolumab_5GGR.png 2x" data-file-width="3564" data-file-height="4096" /></a><div><a href="/wiki/Fragment_antigen-binding" title="Fragment antigen-binding">Fab fragment</a> of nivolumab (blue) binding the <a href="/wiki/Extracellular_domain" class="mw-redirect" title="Extracellular domain">extracellular domain</a> of PD-1 (purple). From <a href="/wiki/Protein_Data_Bank" title="Protein Data Bank">PDB</a> entry <span class="plainlinks"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/pdbe/entry/pdb/5ggr">5ggr</a></span>.</div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd"><a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">Monoclonal antibody</a></th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/File:Engineered_monoclonal_antibodies.svg" title="File:Engineered monoclonal antibodies.svg">Type</a></th><td>Whole antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/Monoclonal_antibody#Production" title="Monoclonal antibody">Source</a></th><td><a href="/wiki/Human" title="Human">Human</a></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/Antigen" title="Antigen">Target</a></th><td><a href="/wiki/Programmed_cell_death_1" class="mw-redirect" title="Programmed cell death 1">PD-1</a></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/Drug_nomenclature#Trade_names" title="Drug nomenclature">Trade names</a></th><td>Opdivo</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Synonyms</th><td>ONO-4538, BMS-936558, MDX1106</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">License data</a></th><td><div class="plainlist">
<ul><li><small><abbr class="country-name" title="European Union">EU</abbr></small>&#160;<a href="/wiki/European_Medicines_Agency" title="European Medicines Agency">EMA</a>:&#160;<span title="www.ema.europa.eu: &#39;Nivolumab&#39;"><a rel="nofollow" class="external text" href="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&amp;mid=&amp;searchTab=searchByKey&amp;alreadyLoaded=true&amp;isNewQuery=true&amp;status=Authorised&amp;status=Withdrawn&amp;status=Suspended&amp;status=Refused&amp;keywordSearch=Submit&amp;searchType=inn&amp;taxonomyPath=&amp;treeNumber=&amp;searchGenericType=generics&amp;keyword=Nivolumab">by INN</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></th><td><div class="plainlist"><ul><li><a href="/wiki/ATC_code_L01" title="ATC code L01">L01XC17</a>&#x20;(<span title="www.whocc.no"><a rel="nofollow" class="external text" href="https://www.whocc.no/atc_ddd_index/?code=L01XC17">WHO</a></span>)&#x20;</li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/CAS_Registry_Number" title="CAS Registry Number">CAS Number</a></th><td><div class="plainlist"><ul><li><span title="www.commonchemistry.org"><a rel="nofollow" class="external text" href="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=946414-94-4">946414-94-4</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/KEGG" title="KEGG">KEGG</a></th><td><div class="plainlist"><ul><li><span title="www.kegg.jp"><a rel="nofollow" class="external text" href="http://www.kegg.jp/entry/D10316">D10316</a></span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></th><td><span title="Carbon">C</span><sub>6362</sub><span title="Hydrogen">H</span><sub>9862</sub><span title="Nitrogen">N</span><sub>1712</sub><span title="Oxygen">O</span><sub>1995</sub><span title="Sulfur">S</span><sub>42</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><a href="/wiki/Molar_mass" title="Molar mass">Molar mass</a></th><td>143.6 kg/mol</td></tr></tbody></table>
<p><b>Nivolumab</b>, marketed as <b>Opdivo</b>, is a medication used to treat <a href="/wiki/Cancer" title="Cancer">cancer</a>.<sup id="cite_ref-INN_1-0" class="reference"><a href="#cite_note-INN-1">&#91;1&#93;</a></sup><sup id="cite_ref-FDALabel_2-0" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup> It is used as a first line treatment for inoperable or <a href="/wiki/Metastatic_melanoma" class="mw-redirect" title="Metastatic melanoma">metastatic melanoma</a> in combination with <a href="/wiki/Ipilimumab" title="Ipilimumab">ipilimumab</a> if the cancer does not have a mutation in <a href="/wiki/BRAF_(gene)" title="BRAF (gene)">BRAF</a>,<sup id="cite_ref-FDALabel_2-1" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup> as a second-line treatment following treatment with ipilimumab and if the cancer has a mutation in BRAF, with a <a href="/wiki/BRAF_inhibitor" class="mw-redirect" title="BRAF inhibitor">BRAF inhibitor</a>,<sup id="cite_ref-2015revMel_3-0" class="reference"><a href="#cite_note-2015revMel-3">&#91;3&#93;</a></sup>  as a second-line treatment for <a href="/wiki/Non-small_cell_lung_cancer" class="mw-redirect" title="Non-small cell lung cancer">squamous non-small cell lung cancer</a>,<sup id="cite_ref-2015revNSCLC_4-0" class="reference"><a href="#cite_note-2015revNSCLC-4">&#91;4&#93;</a></sup> and as a second-line treatment for <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a>.<sup id="cite_ref-FDALabel_2-2" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup>
</p><p>It had not been tested in pregnant women but based on the mechanism of action and animal studies, is probably toxic to the fetus; it is not known if it is secreted in breast milk. Side effects include severe immune-related inflammation of the lungs, colon, liver, kidneys, and thyroid, and there are effects on skin, central nervous system, the heart, and the digestive system.<sup id="cite_ref-FDALabel_2-3" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup>
</p><p>It is a human <a href="/wiki/Immunoglobulin_G" title="Immunoglobulin G">IgG4</a> anti-<a href="/wiki/PD-1" class="mw-redirect" title="PD-1">PD-1</a> <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a>. Nivolumab works as a <a href="/wiki/Checkpoint_inhibitor" title="Checkpoint inhibitor">checkpoint inhibitor</a>, blocking a signal that would have prevented activated <a href="/wiki/T_cells" class="mw-redirect" title="T cells">T cells</a> from attacking the cancer, thus allowing the immune system to clear the cancer. It was discovered at <a href="/wiki/Medarex" title="Medarex">Medarex</a>, developed by Medarex and <a href="/wiki/Ono_Pharmaceutical" title="Ono Pharmaceutical">Ono Pharmaceutical</a>, and brought to market by <a href="/wiki/Bristol-Myers_Squibb" title="Bristol-Myers Squibb">Bristol-Myers Squibb</a> (which acquired Medarex in 2009) and Ono.
</p>
<div id="toc" class="toc"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2>Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Medical_use"><span class="tocnumber">1</span> <span class="toctext">Medical use</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Side_effects"><span class="tocnumber">2</span> <span class="toctext">Side effects</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Pharmacokinetics"><span class="tocnumber">3</span> <span class="toctext">Pharmacokinetics</span></a></li>
<li class="toclevel-1 tocsection-4"><a href="#Mechanism_of_action"><span class="tocnumber">4</span> <span class="toctext">Mechanism of action</span></a></li>
<li class="toclevel-1 tocsection-5"><a href="#Physical_properties"><span class="tocnumber">5</span> <span class="toctext">Physical properties</span></a></li>
<li class="toclevel-1 tocsection-6"><a href="#History"><span class="tocnumber">6</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1 tocsection-7"><a href="#Research"><span class="tocnumber">7</span> <span class="toctext">Research</span></a>
<ul>
<li class="toclevel-2 tocsection-8"><a href="#Hodgkin&#39;s_lymphoma"><span class="tocnumber">7.1</span> <span class="toctext">Hodgkin's lymphoma</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Biomarkers"><span class="tocnumber">7.2</span> <span class="toctext">Biomarkers</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Lung_cancer"><span class="tocnumber">7.3</span> <span class="toctext">Lung cancer</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-11"><a href="#References"><span class="tocnumber">8</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h2><span class="mw-headline" id="Medical_use">Medical use</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=1" title="Edit section: Medical use">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Nivolumab is used as a first line treatment for inoperable or <a href="/wiki/Metastatic_melanoma" class="mw-redirect" title="Metastatic melanoma">metastatic melanoma</a> in combination with <a href="/wiki/Ipilimumab" title="Ipilimumab">ipilimumab</a> if the cancer does not have a mutation in <a href="/wiki/BRAF_(gene)" title="BRAF (gene)">BRAF</a>,<sup id="cite_ref-FDALabel_2-4" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup>  and as a second-line treatment for inoperable or metastatic melanoma following treatment of <a href="/wiki/Ipilimumab" title="Ipilimumab">ipilimumab</a> and, if the cancer has a BRAF mutation, a <a href="/wiki/BRAF_inhibitor" class="mw-redirect" title="BRAF inhibitor">BRAF inhibitor</a>.<sup id="cite_ref-FDALabel_2-5" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup><sup id="cite_ref-2015revMel_3-1" class="reference"><a href="#cite_note-2015revMel-3">&#91;3&#93;</a></sup> It is also used to treat metastatic squamous <a href="/wiki/Non-small_cell_lung_cancer" class="mw-redirect" title="Non-small cell lung cancer">non-small cell lung cancer</a> with progression with or after <a href="/wiki/Platinum-based_antineoplastic" title="Platinum-based antineoplastic">platinum-based drugs</a>.<sup id="cite_ref-FDALabel_2-6" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup><sup id="cite_ref-2015revNSCLC_4-1" class="reference"><a href="#cite_note-2015revNSCLC-4">&#91;4&#93;</a></sup> It also used as a second-line treatment for <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a> after anti-angiogenic treatment has failed.<sup id="cite_ref-FDALabel_2-7" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup>
</p><p>FDA has approved nivolumab for primary or metastatic <a href="/wiki/Urothelial_carcinoma" class="mw-redirect" title="Urothelial carcinoma">urothelial carcinoma</a>, the most common form of <a href="/wiki/Bladder_cancer" title="Bladder cancer">bladder cancer</a>. It can be prescribed for locally advanced or metastatic form of the condition that experience disease progression during or following <a href="/wiki/Platinum-based_antineoplastic" title="Platinum-based antineoplastic">platinum-containing chemotherapy</a> or have progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">&#91;5&#93;</a></sup>
</p><p>Nivolumab was not tested in pregnant women but based on how the drug works and on animal studies, it is likely to cause harm to a baby; it is not known if nivolumab is secreted in breast milk.<sup id="cite_ref-FDALabel_2-8" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup>
</p><p>Nivolumab, and other PD-1 inhibitors, appear to be effective in people with brain metastases<sup id="cite_ref-6" class="reference"><a href="#cite_note-6">&#91;6&#93;</a></sup> and autoimmune diseases.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7">&#91;7&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Side_effects">Side effects</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=2" title="Edit section: Side effects">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The drug label contains warnings with regard to increased risks of severe immune-mediated inflammation of <a href="/wiki/Pneumonitis" title="Pneumonitis">the lungs</a>, <a href="/wiki/Colitis" title="Colitis">the colon</a>, <a href="/wiki/Hepatitis" title="Hepatitis">the liver</a>, <a href="/wiki/Nephritis" title="Nephritis">the kidneys</a> (with accompanying kidney dysfunction), as well as immune-mediated <a href="/wiki/Hypothyroidism" title="Hypothyroidism">hypothyroidism</a> and <a href="/wiki/Hyperthyroidism" title="Hyperthyroidism">hyperthyroidism</a>.<sup id="cite_ref-FDALabel_2-9" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup>
</p><p>In clinical trials for melanoma, the following side effects occurred in more than 10% of subjects and more frequently than with chemotherapy alone: rash and itchy skin, cough, upper respiratory tract infections, and peripheral edema. Other clinically important side effects with less than 10% frequency were ventricular arrhythmia, inflammation of parts of the eye (<a href="/wiki/Iridocyclitis" class="mw-redirect" title="Iridocyclitis">iridocyclitis</a>), infusion-related reactions, dizziness, peripheral and sensory neuropathy, peeling skin, <a href="/wiki/Erythema_multiforme" title="Erythema multiforme">erythema multiforme</a>, <a href="/wiki/Vitiligo" title="Vitiligo">vitiligo</a>, and psoriasis.<sup id="cite_ref-FDALabel_2-10" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup>
</p><p>In clinical trials for lung cancer, the following side effects occurred in more than 10% of subjects and more frequently than with chemotherapy alone: fatigue, weakness, edema, fever, chest pain, generalized pain, shortness of breath, cough, muscle and joint pain, decreased appetite, abdominal pain, nausea and vomiting, constipation, weight loss, rash, and itchy skin.<sup id="cite_ref-FDALabel_2-11" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup>
</p><p>Levels of electrolytes and blood cells counts were also disrupted.<sup id="cite_ref-FDALabel_2-12" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Pharmacokinetics">Pharmacokinetics</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=3" title="Edit section: Pharmacokinetics">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Based on data from 909 patients, the <a href="/wiki/Terminal_half-life" class="mw-redirect" title="Terminal half-life">terminal half-life</a> of nivolumab is 26.7 days and steady-state concentrations were reached by 12 weeks when administered at 3&#160;mg/kg every 2 weeks.<sup id="cite_ref-FDALabel_2-13" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup><sup class="reference" style="white-space:nowrap;">:<span>29</span></sup> Age, gender, race, baseline LDH, PD-L1 expression, tumor type, tumor size, renal impairment, and mild hepatic impairment do not affect clearance of the drug.<sup id="cite_ref-FDALabel_2-14" class="reference"><a href="#cite_note-FDALabel-2">&#91;2&#93;</a></sup><sup class="reference" style="white-space:nowrap;">:<span>30</span></sup>
</p>
<h2><span class="mw-headline" id="Mechanism_of_action">Mechanism of action</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=4" title="Edit section: Mechanism of action">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p><a href="/wiki/T_cells" class="mw-redirect" title="T cells">T cells</a> protect the body from cancer by killing certain cancer cells. But cancer cells evolve proteins to protect themselves from T cells. Nivolumab blocks those protective proteins. Thus, the T cells can kill the cancer cells.<sup id="cite_ref-Pardoll2012_8-0" class="reference"><a href="#cite_note-Pardoll2012-8">&#91;8&#93;</a></sup><sup id="cite_ref-:0_9-0" class="reference"><a href="#cite_note-:0-9">&#91;9&#93;</a></sup> This is an example of <a href="/wiki/Immune_checkpoint_blockade" class="mw-redirect" title="Immune checkpoint blockade">immune checkpoint blockade</a>.<sup id="cite_ref-Pardoll2012_8-1" class="reference"><a href="#cite_note-Pardoll2012-8">&#91;8&#93;</a></sup><sup id="cite_ref-:0_9-1" class="reference"><a href="#cite_note-:0-9">&#91;9&#93;</a></sup>
</p><p>PD-1 is a protein on the surface of activated T cells. If another molecule, called <a href="/wiki/Programmed_cell_death_1_ligand_1" class="mw-redirect" title="Programmed cell death 1 ligand 1">programmed cell death 1 ligand 1</a> or programmed cell death 1 ligand 2 (PD-L1 or PD-L2), binds to PD-1, the T cell becomes inactive. This is one way that the body regulates the immune system, to avoid an overreaction.<sup id="cite_ref-:0_9-2" class="reference"><a href="#cite_note-:0-9">&#91;9&#93;</a></sup> Many cancer cells make PD-L1, which inhibits T cells from attacking the tumor. Nivolumab blocks PD-L1 from binding to PD-1, allowing the T cell to work.<sup id="cite_ref-Pardoll2012_8-2" class="reference"><a href="#cite_note-Pardoll2012-8">&#91;8&#93;</a></sup><sup id="cite_ref-:0_9-3" class="reference"><a href="#cite_note-:0-9">&#91;9&#93;</a></sup> PD-L1 is expressed on 40–50% of melanomas and has limited expression otherwise in most visceral organs with the exception of respiratory epithelium and placental tissue.<sup id="cite_ref-2015revMel_3-2" class="reference"><a href="#cite_note-2015revMel-3">&#91;3&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Physical_properties">Physical properties</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=5" title="Edit section: Physical properties">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Nivolumab is a fully human monoclonal <a href="/wiki/Immunoglobulin_G" title="Immunoglobulin G">immunoglobulin G</a>4  antibody to <a href="/wiki/PD-1" class="mw-redirect" title="PD-1">PD-1</a>.<sup id="cite_ref-2015revMel_3-3" class="reference"><a href="#cite_note-2015revMel-3">&#91;3&#93;</a></sup> The gamma 1 heavy chain is 91.8% unmodified human design while the kappa light chain is 98.9%.<sup id="cite_ref-INN_1-1" class="reference"><a href="#cite_note-INN-1">&#91;1&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=6" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Nivolumab was created by scientists at <a href="/wiki/Medarex" title="Medarex">Medarex</a> using Medarex's <a href="/wiki/Transgenic_mice" class="mw-redirect" title="Transgenic mice">transgenic mice</a> with a humanized immune system; the discovery and <i>in vitro</i> characterization of the antibody, originally called MDX-1106, was published (much later) in 2014.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10">&#91;10&#93;</a></sup> Medarex licensed Japanese rights to nivolumab to <a href="/wiki/Ono_Pharmaceutical" title="Ono Pharmaceutical">Ono Pharmaceutical</a> in 2005.<sup id="cite_ref-FierceJapanApp_11-0" class="reference"><a href="#cite_note-FierceJapanApp-11">&#91;11&#93;</a></sup> <a href="/wiki/Bristol-Myers_Squibb" title="Bristol-Myers Squibb">Bristol-Myers Squibb</a> acquired Medarex in 2009 for $2.4B, largely on the strength of its checkpoint inhibitor program.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12">&#91;12&#93;</a></sup><sup id="cite_ref-13" class="reference"><a href="#cite_note-13">&#91;13&#93;</a></sup>
</p><p>Promising clinical trial results made public in 2012 caused excitement among industry analysts and in the mainstream media; PD-1 was being avidly pursued as a <a href="/wiki/Biological_target" title="Biological target">biological target</a> at that time, with companies including <a href="/wiki/Merck_%26_Co." title="Merck &amp; Co.">Merck</a> with <a href="/wiki/Pembrolizumab" title="Pembrolizumab">pembrolizumab</a> (Keytruda), <a href="/wiki/Hoffmann-La_Roche" title="Hoffmann-La Roche">Roche</a> (via its subsidiary <a href="/wiki/Genentech" title="Genentech">Genentech</a>) with <a href="/wiki/Atezolizumab" title="Atezolizumab">atezolizumab</a>, <a href="/wiki/GlaxoSmithKline" title="GlaxoSmithKline">GlaxoSmithKline</a> in collaboration with the Maryland biotech company <a href="/w/index.php?title=Amplimmune&amp;action=edit&amp;redlink=1" class="new" title="Amplimmune (page does not exist)">Amplimmune</a>; and <a href="/wiki/Teva_Pharmaceutical_Industries" title="Teva Pharmaceutical Industries">Teva</a> in collaboration with the Israeli biotech company <a href="/w/index.php?title=CureTech&amp;action=edit&amp;redlink=1" class="new" title="CureTech (page does not exist)">CureTech</a> competing.<sup id="cite_ref-Science2015rev_14-0" class="reference"><a href="#cite_note-Science2015rev-14">&#91;14&#93;</a></sup><sup id="cite_ref-PollackNYT2015_15-0" class="reference"><a href="#cite_note-PollackNYT2015-15">&#91;15&#93;</a></sup>
</p><p>Ono received approval from Japanese regulatory authorities to use nivolumab to treat unresectable melanoma in July 2014, which was the first regulatory approval of a PD-1 inhibitor anywhere in the world.<sup id="cite_ref-FierceJapanApp_11-1" class="reference"><a href="#cite_note-FierceJapanApp-11">&#91;11&#93;</a></sup>
</p><p>Merck received its first FDA approval for its PD-1 inhibitor, pembrolizumab (Keytruda), in September 2014.<sup id="cite_ref-16" class="reference"><a href="#cite_note-16">&#91;16&#93;</a></sup>
</p><p>Nivolumab received FDA approval for the treatment of melanoma in December 2014.<sup id="cite_ref-2015revMel_3-4" class="reference"><a href="#cite_note-2015revMel-3">&#91;3&#93;</a></sup><sup id="cite_ref-17" class="reference"><a href="#cite_note-17">&#91;17&#93;</a></sup>  In April 2015, the <a href="/wiki/Committee_for_Medicinal_Products_for_Human_Use" title="Committee for Medicinal Products for Human Use">Committee for Medicinal Products for Human Use</a> of the <a href="/wiki/European_Medicines_Agency" title="European Medicines Agency">European Medicines Agency</a> recommended approval of Nivolumab for metastatic melanoma as a <a href="/wiki/Monotherapy" class="mw-redirect" title="Monotherapy">monotherapy</a>.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18">&#91;18&#93;</a></sup>
</p><p>In March 2015, the US FDA approved it for the treatment of <a href="/wiki/Squamous-cell_carcinoma_of_the_lung" title="Squamous-cell carcinoma of the lung">squamous cell lung cancer</a>.<sup id="cite_ref-FDA2015-Mar_19-0" class="reference"><a href="#cite_note-FDA2015-Mar-19">&#91;19&#93;</a></sup>
</p><p>On 19 June 2015 the <a href="/wiki/European_Commission" title="European Commission">European Commission</a> granted a marketing authorisation valid throughout the <a href="/wiki/European_Union" title="European Union">European Union</a>.<sup id="cite_ref-20" class="reference"><a href="#cite_note-20">&#91;20&#93;</a></sup>
</p><p>In November 2015, the FDA approved nivolumab as a second-line treatment for <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a> after having granted the application <a href="/wiki/Breakthrough_therapy" title="Breakthrough therapy">breakthrough therapy</a> designation, <a href="/wiki/Fast_track_(FDA)" title="Fast track (FDA)">fast track</a> designation, and <a href="/wiki/Priority_review_(FDA)" class="mw-redirect" title="Priority review (FDA)">priority review</a> status.<sup id="cite_ref-FDApress2015renal_21-0" class="reference"><a href="#cite_note-FDApress2015renal-21">&#91;21&#93;</a></sup>
</p><p>In May 2016, the FDA approved nivolumab for the treatment of patients with <a href="/wiki/Classical_Hodgkin_lymphoma" class="mw-redirect" title="Classical Hodgkin lymphoma">classical Hodgkin lymphoma</a> (cHL) who have relapsed or progressed after <a href="/wiki/Autologous_hematopoietic_stem_cell_transplantation" class="mw-redirect" title="Autologous hematopoietic stem cell transplantation">autologous hematopoietic stem cell transplantation</a> (auto-HSCT) and post-transplantation <a href="/wiki/Brentuximab_vedotin" title="Brentuximab vedotin">brentuximab vedotin</a>.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22">&#91;22&#93;</a></sup>
</p><p>On December 20, 2017, the FDA granted approval to nivolumab for adjuvant treatment of melanoma with involvement of lymph nodes or for metastatic disease with complete resection.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23">&#91;23&#93;</a></sup>
</p><p>On April 16, 2018, the FDA granted approval to nivolumab in combination with <a href="/wiki/Ipilimumab" title="Ipilimumab">ipilimumab</a> for the first-line treatment of intermediate and poor risk advanced <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a> patients.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24">&#91;24&#93;</a></sup>
</p><p>On June 15, 2018, China’s Drug Administration approved nivolumab, the country’s first immuno-oncology and the first PD-1 therapy.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25">&#91;25&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Research">Research</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=7" title="Edit section: Research">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span id="Hodgkin.27s_lymphoma"></span><span class="mw-headline" id="Hodgkin's_lymphoma">Hodgkin's lymphoma</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=8" title="Edit section: Hodgkin&#039;s lymphoma">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In <a href="/wiki/Hodgkin%27s_lymphoma" title="Hodgkin&#39;s lymphoma">Hodgkin's lymphoma</a>, <a href="/wiki/Reed%E2%80%93Sternberg_cell" title="Reed–Sternberg cell">Reed-Sternberg cells</a> harbor amplification of <a href="/wiki/Chromosome_9" title="Chromosome 9">chromosome 9p</a>24.1, which encodes PD-L1 and PD-L2 and leads to their constitutive expression. In a small clinical study published in 2015, nivolumab elicited an objective response rate of 87% in a cohort of 20 patients.<sup id="cite_ref-Science2015rev_14-1" class="reference"><a href="#cite_note-Science2015rev-14">&#91;14&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Biomarkers">Biomarkers</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=9" title="Edit section: Biomarkers">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Amplification of chromosome 9p24 may serve as a predictive biomarker in Hodgkin’s lymphoma.<sup id="cite_ref-Science2015rev_14-2" class="reference"><a href="#cite_note-Science2015rev-14">&#91;14&#93;</a></sup>
</p><p>Each company pursuing mAbs against PD-1 as drugs developed assays to measure PD-L1 levels as a potential biomarker using their drugs as the <a href="/wiki/Analyte-specific_reagent" title="Analyte-specific reagent">analyte-specific reagent</a> in the assay. BMS partnered with Dako on a nivolumab-based assay. However, as of 2015 the complexity of the immune response had hindered efforts to identify people who would be likely to respond well to PD-1 inhibitors;<sup id="cite_ref-Science2015rev_14-3" class="reference"><a href="#cite_note-Science2015rev-14">&#91;14&#93;</a></sup> in particular PD-L1 levels appear to be dynamic and modulated by several factors, and efforts to correlate PD-L1 levels before or during treatment with treatment response or duration of response had failed to reveal any useful correlations as of 2015.<sup id="cite_ref-2015revMel_3-5" class="reference"><a href="#cite_note-2015revMel-3">&#91;3&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Lung_cancer">Lung cancer</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=10" title="Edit section: Lung cancer">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In 2016, BMS announced the results of a clinical trial in which nivolumab failed to achieve its endpoint and was no better than traditional chemotherapy at treating newly diagnosed lung cancer.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">&#91;26&#93;</a></sup> BMS went on to attempt to win approval for a combination therapy against lung cancer which included nivolumab and BMS's older drug ipilimumab. The application was withdrawn in early 2019 following disappointing clinical trial data.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27">&#91;27&#93;</a></sup>
</p><p>Infusion times of 60 minutes and 30 minutes appear to have similar pharmacokinetics (absorption, distribution, metabolism, and elimination) of the treatment.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28">&#91;28&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Nivolumab&amp;action=edit&amp;section=11" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist" style="list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-INN-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-INN_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-INN_1-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">WHO Drug Information, Vol. 26, No. 2, 2012. <a rel="nofollow" class="external text" href="http://www.who.int/medicines/publications/druginformation/innlists/PL107.pdf?ua=1">Proposed INN List 107</a></span>
</li>
<li id="cite_note-FDALabel-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDALabel_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDALabel_2-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDALabel_2-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDALabel_2-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDALabel_2-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDALabel_2-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDALabel_2-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-FDALabel_2-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-FDALabel_2-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-FDALabel_2-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-FDALabel_2-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-FDALabel_2-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-FDALabel_2-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-FDALabel_2-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-FDALabel_2-14"><sup><i><b>o</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s012lbl.pdf">Nivolumab Label</a>. Last updated Nov 2015.</span>
</li>
<li id="cite_note-2015revMel-3"><span class="mw-cite-backlink">^ <a href="#cite_ref-2015revMel_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-2015revMel_3-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-2015revMel_3-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-2015revMel_3-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-2015revMel_3-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-2015revMel_3-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Johnson DB, Peng C, Sosman JA (March 2015). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4346215">"Nivolumab in melanoma: latest evidence and clinical potential"</a>. <i>Therapeutic Advances in Medical Oncology</i>. <b>7</b> (2): 97–106. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1177%2F1758834014567469">10.1177/1758834014567469</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4346215">4346215</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25755682">25755682</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Therapeutic+Advances+in+Medical+Oncology&amp;rft.atitle=Nivolumab+in+melanoma%3A+latest+evidence+and+clinical+potential&amp;rft.volume=7&amp;rft.issue=2&amp;rft.pages=97-106&amp;rft.date=2015-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4346215&amp;rft_id=info%3Apmid%2F25755682&amp;rft_id=info%3Adoi%2F10.1177%2F1758834014567469&amp;rft.aulast=Johnson&amp;rft.aufirst=DB&amp;rft.au=Peng%2C+C&amp;rft.au=Sosman%2C+JA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4346215&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><style data-mw-deduplicate="TemplateStyles:r879151008">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}</style></span>
</li>
<li id="cite_note-2015revNSCLC-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-2015revNSCLC_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-2015revNSCLC_4-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Sundar R, Cho BC, Brahmer JR, Soo RA (March 2015). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4346216">"Nivolumab in NSCLC: latest evidence and clinical potential"</a>. <i>Therapeutic Advances in Medical Oncology</i>. <b>7</b> (2): 85–96. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1177%2F1758834014567470">10.1177/1758834014567470</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4346216">4346216</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25755681">25755681</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Therapeutic+Advances+in+Medical+Oncology&amp;rft.atitle=Nivolumab+in+NSCLC%3A+latest+evidence+and+clinical+potential&amp;rft.volume=7&amp;rft.issue=2&amp;rft.pages=85-96&amp;rft.date=2015-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4346216&amp;rft_id=info%3Apmid%2F25755681&amp;rft_id=info%3Adoi%2F10.1177%2F1758834014567470&amp;rft.aulast=Sundar&amp;rft.aufirst=R&amp;rft.au=Cho%2C+BC&amp;rft.au=Brahmer%2C+JR&amp;rft.au=Soo%2C+RA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4346216&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text">Bushey, R. <a rel="nofollow" class="external text" href="http://www.dddmag.com/article/2017/02/opdivo-gains-fda-approval-common-bladder-cancer?et_cid=5813686&amp;et_rid=297252576&amp;type=headline&amp;et_cid=5813686&amp;et_rid=297252576&amp;linkid=content%7COpdivo">Gains FDA Approval for Common Bladder Cancer</a>.  Drug Discovery &amp; Development, Fri, 02/03/2017.</span>
</li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><cite class="citation journal">Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, Donia M (May 2018). "Cancer immunotherapy in patients with brain metastases". <i>Cancer Immunology, Immunotherapy</i>. <b>67</b> (5): 703–711. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1007%2Fs00262-018-2146-8">10.1007/s00262-018-2146-8</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/29520474">29520474</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Immunology%2C+Immunotherapy&amp;rft.atitle=Cancer+immunotherapy+in+patients+with+brain+metastases&amp;rft.volume=67&amp;rft.issue=5&amp;rft.pages=703-711&amp;rft.date=2018-05&amp;rft_id=info%3Adoi%2F10.1007%2Fs00262-018-2146-8&amp;rft_id=info%3Apmid%2F29520474&amp;rft.aulast=Caponnetto&amp;rft.aufirst=S&amp;rft.au=Draghi%2C+A&amp;rft.au=Borch%2C+TH&amp;rft.au=Nuti%2C+M&amp;rft.au=Cortesi%2C+E&amp;rft.au=Svane%2C+IM&amp;rft.au=Donia%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><cite class="citation journal">Donia M, Pedersen M, Svane IM (April 2017). "Cancer immunotherapy in patients with preexisting autoimmune disorders". <i>Seminars in Immunopathology</i>. <b>39</b> (3): 333–337. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1007%2Fs00281-016-0595-8">10.1007/s00281-016-0595-8</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27730287">27730287</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Seminars+in+Immunopathology&amp;rft.atitle=Cancer+immunotherapy+in+patients+with+preexisting+autoimmune+disorders&amp;rft.volume=39&amp;rft.issue=3&amp;rft.pages=333-337&amp;rft.date=2017-04&amp;rft_id=info%3Adoi%2F10.1007%2Fs00281-016-0595-8&amp;rft_id=info%3Apmid%2F27730287&amp;rft.aulast=Donia&amp;rft.aufirst=M&amp;rft.au=Pedersen%2C+M&amp;rft.au=Svane%2C+IM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-Pardoll2012-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-Pardoll2012_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Pardoll2012_8-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Pardoll2012_8-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Pardoll DM (March 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023">"The blockade of immune checkpoints in cancer immunotherapy"</a>. <i>Nature Reviews. Cancer</i>. <b>12</b> (4): 252–64. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnrc3239">10.1038/nrc3239</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023">4856023</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22437870">22437870</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Cancer&amp;rft.atitle=The+blockade+of+immune+checkpoints+in+cancer+immunotherapy&amp;rft.volume=12&amp;rft.issue=4&amp;rft.pages=252-64&amp;rft.date=2012-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4856023&amp;rft_id=info%3Apmid%2F22437870&amp;rft_id=info%3Adoi%2F10.1038%2Fnrc3239&amp;rft.aulast=Pardoll&amp;rft.aufirst=DM&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4856023&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-:0-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_9-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:0_9-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:0_9-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". <i>The Lancet. Oncology</i>. <b>18</b> (12): e731–e741. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fs1470-2045%2817%2930607-1">10.1016/s1470-2045(17)30607-1</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/29208439">29208439</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Lancet.+Oncology&amp;rft.atitle=De-novo+and+acquired+resistance+to+immune+checkpoint+targeting&amp;rft.volume=18&amp;rft.issue=12&amp;rft.pages=e731-e741&amp;rft.date=2017-12&amp;rft_id=info%3Adoi%2F10.1016%2Fs1470-2045%2817%2930607-1&amp;rft_id=info%3Apmid%2F29208439&amp;rft.aulast=Syn&amp;rft.aufirst=NL&amp;rft.au=Teng%2C+MW&amp;rft.au=Mok%2C+TS&amp;rft.au=Soo%2C+RA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text"><cite class="citation journal">Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ (September 2014). "In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates". <i>Cancer Immunology Research</i>. <b>2</b> (9): 846–56. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1158%2F2326-6066.CIR-14-0040">10.1158/2326-6066.CIR-14-0040</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24872026">24872026</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Immunology+Research&amp;rft.atitle=In+vitro+characterization+of+the+anti-PD-1+antibody+nivolumab%2C+BMS-936558%2C+and+in+vivo+toxicology+in+non-human+primates&amp;rft.volume=2&amp;rft.issue=9&amp;rft.pages=846-56&amp;rft.date=2014-09&amp;rft_id=info%3Adoi%2F10.1158%2F2326-6066.CIR-14-0040&amp;rft_id=info%3Apmid%2F24872026&amp;rft.aulast=Wang&amp;rft.aufirst=C&amp;rft.au=Thudium%2C+KB&amp;rft.au=Han%2C+M&amp;rft.au=Wang%2C+XT&amp;rft.au=Huang%2C+H&amp;rft.au=Feingersh%2C+D&amp;rft.au=Garcia%2C+C&amp;rft.au=Wu%2C+Y&amp;rft.au=Kuhne%2C+M&amp;rft.au=Srinivasan%2C+M&amp;rft.au=Singh%2C+S&amp;rft.au=Wong%2C+S&amp;rft.au=Garner%2C+N&amp;rft.au=Leblanc%2C+H&amp;rft.au=Bunch%2C+RT&amp;rft.au=Blanset%2C+D&amp;rft.au=Selby%2C+MJ&amp;rft.au=Korman%2C+AJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-FierceJapanApp-11"><span class="mw-cite-backlink">^ <a href="#cite_ref-FierceJapanApp_11-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FierceJapanApp_11-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">John Carroll for FierceBiotech Jul 7, 2014 <a rel="nofollow" class="external text" href="http://www.fiercebiotech.com/biotech/anti-pd-1-cancer-star-nivolumab-wins-world-s-first-regulatory-approval">Anti-PD-1 cancer star nivolumab wins world's first regulatory approval</a></span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><cite class="citation journal">Allison M (September 2009). "Bristol-Myers Squibb swallows last of antibody pioneers". <i>Nature Biotechnology</i>. <b>27</b> (9): 781–3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnbt0909-781">10.1038/nbt0909-781</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19741612">19741612</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Biotechnology&amp;rft.atitle=Bristol-Myers+Squibb+swallows+last+of+antibody+pioneers&amp;rft.volume=27&amp;rft.issue=9&amp;rft.pages=781-3&amp;rft.date=2009-09&amp;rft_id=info%3Adoi%2F10.1038%2Fnbt0909-781&amp;rft_id=info%3Apmid%2F19741612&amp;rft.aulast=Allison&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text">John Carroll for FierceBiotech Jul 23, 2009 <a rel="nofollow" class="external text" href="http://www.fiercebiotech.com/biotech/bristol-myers-to-buy-medarex-for-2-1b">Bristol-Myers to buy Medarex for $2.1B</a></span>
</li>
<li id="cite_note-Science2015rev-14"><span class="mw-cite-backlink">^ <a href="#cite_ref-Science2015rev_14-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Science2015rev_14-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Science2015rev_14-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Science2015rev_14-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Sharma P, Allison JP (April 2015). "The future of immune checkpoint therapy". <i>Science</i>. <b>348</b> (6230): 56–61. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1126%2Fscience.aaa8172">10.1126/science.aaa8172</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25838373">25838373</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science&amp;rft.atitle=The+future+of+immune+checkpoint+therapy&amp;rft.volume=348&amp;rft.issue=6230&amp;rft.pages=56-61&amp;rft.date=2015-04&amp;rft_id=info%3Adoi%2F10.1126%2Fscience.aaa8172&amp;rft_id=info%3Apmid%2F25838373&amp;rft.aulast=Sharma&amp;rft.aufirst=P&amp;rft.au=Allison%2C+JP&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-PollackNYT2015-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-PollackNYT2015_15-0">^</a></b></span> <span class="reference-text"><cite class="citation web">A Pollack (June 2012). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2012/06/02/business/drug-helps-immune-system-fight-cancer.html">"Drug helps immune system fight cancer"</a>. <i>New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=New+York+Times&amp;rft.atitle=Drug+helps+immune+system+fight+cancer.&amp;rft.date=2012-06&amp;rft.au=A+Pollack&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2012%2F06%2F02%2Fbusiness%2Fdrug-helps-immune-system-fight-cancer.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text"><cite class="citation news">U.S. Food and Drug Administration (September 4, 2014). <a rel="nofollow" class="external text" href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm">"FDA approves Keytruda for advanced melanoma"</a>. U.S. Food and Drug Administration. U.S. Food and Drug Administration<span class="reference-accessdate">. Retrieved <span class="nowrap">24 December</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=FDA+approves+Keytruda+for+advanced+melanoma&amp;rft.date=2014-09-04&amp;rft.au=U.S.+Food+and+Drug+Administration&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm412802.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm">"FDA approves Opdivo for advanced melanoma"</a>. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a>. December 22, 2014.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+approves+Opdivo+for+advanced+melanoma&amp;rft.pub=Food+and+Drug+Administration&amp;rft.date=2014-12-22&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm427716.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002314.jsp&amp;mid=WC0b01ac058004d5c1">"Press Release: New treatment for advanced melanoma"</a>. <i>European Medicines Agency</i><span class="reference-accessdate">. Retrieved <span class="nowrap">5 May</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=European+Medicines+Agency&amp;rft.atitle=Press+Release%3A+New+treatment+for+advanced+melanoma&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Findex.jsp%3Fcurl%3Dpages%2Fnews_and_events%2Fnews%2F2015%2F04%2Fnews_detail_002314.jsp%26mid%3DWC0b01ac058004d5c1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-FDA2015-Mar-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-FDA2015-Mar_19-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm">"FDA expands approved use of Opdivo to treat lung cancer (FDA.gov)"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">March 4,</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+expands+approved+use+of+Opdivo+to+treat+lung+cancer+%28FDA.gov%29&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm436534.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003985/WC500189768.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003985/WC500189768.pdf</a></span>
</li>
<li id="cite_note-FDApress2015renal-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-FDApress2015renal_21-0">^</a></b></span> <span class="reference-text">FDA. November 23, 2015 <a rel="nofollow" class="external text" href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm">FDA Press Release: FDA approves Opdivo to treat advanced form of kidney cancer</a></span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><cite class="citation web">Research, Center for Drug Evaluation and. <a rel="nofollow" class="external text" href="http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501412.htm">"Approved Drugs - Nivolumab (Opdivo) for Hodgkin Lymphoma"</a>. <i>www.fda.gov</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fda.gov&amp;rft.atitle=Approved+Drugs+-+Nivolumab+%28Opdivo%29+for+Hodgkin+Lymphoma&amp;rft.aulast=Research&amp;rft.aufirst=Center+for+Drug+Evaluation+and&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm501412.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><cite class="citation web">Research, Center for Drug Evaluation and. <a rel="nofollow" class="external text" href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590004.htm">"Approved Drugs - FDA grants regular approval to nivolumab for adjuvant treatment of melanoma"</a>. <i>www.fda.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2018-04-12</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fda.gov&amp;rft.atitle=Approved+Drugs+-+FDA+grants+regular+approval+to+nivolumab+for+adjuvant+treatment+of+melanoma&amp;rft.aulast=Research&amp;rft.aufirst=Center+for+Drug+Evaluation+and&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm590004.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><cite class="citation web">Research, Center for Drug Evaluation and. <a rel="nofollow" class="external text" href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm">"Approved Drugs - FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma"</a>. <i>www.fda.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2018-04-20</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fda.gov&amp;rft.atitle=Approved+Drugs+-+FDA+approves+nivolumab+plus+ipilimumab+combination+for+intermediate+or+poor-risk+advanced+renal+cell+carcinoma&amp;rft.aulast=Research&amp;rft.aufirst=Center+for+Drug+Evaluation+and&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm604685.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.fiercepharma.com/pharma-asia/opdivo-for-lung-cancer-first-i-o-therapy-approved-china">"Bristol-Myers' Opdivo ushers in a new era as the first I-O therapy approved in China | FiercePharma"</a>. <i>www.fiercepharma.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2018-06-19</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fiercepharma.com&amp;rft.atitle=Bristol-Myers%E2%80%99+Opdivo+ushers+in+a+new+era+as+the+first+I-O+therapy+approved+in+China+%7C+FiercePharma&amp;rft_id=https%3A%2F%2Fwww.fiercepharma.com%2Fpharma-asia%2Fopdivo-for-lung-cancer-first-i-o-therapy-approved-china&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><cite class="citation news">Loftus P, Rockoff JD, Steele A (2016-08-05). <a rel="nofollow" class="external text" href="https://www.wsj.com/articles/bristol-myers-opdivo-failed-to-meet-endpoint-in-key-lung-cancer-study-1470400926">"Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study"</a>. <i>Wall Street Journal</i>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0099-9660">0099-9660</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2016-08-21</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Wall+Street+Journal&amp;rft.atitle=Bristol+Myers%3A+Opdivo+Failed+to+Meet+Endpoint+in+Key+Lung-Cancer+Study&amp;rft.date=2016-08-05&amp;rft.issn=0099-9660&amp;rft.aulast=Loftus&amp;rft.aufirst=Peter&amp;rft.au=Rockoff%2C+Jonathan+D.&amp;rft.au=Steele%2C+Anne&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2Fbristol-myers-opdivo-failed-to-meet-endpoint-in-key-lung-cancer-study-1470400926&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><cite class="citation news">Erman, Michael (24 January 2019). <a rel="nofollow" class="external text" href="https://finance.yahoo.com/news/bristol-myers-opdivo-lung-cancer-172155354.html">"Bristol-Myers has Opdivo lung cancer setback as sales beat estimates"</a>. <i><a href="/wiki/Reuters" title="Reuters">Reuters</a></i><span class="reference-accessdate">. Retrieved <span class="nowrap">24 January</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Reuters&amp;rft.atitle=Bristol-Myers+has+Opdivo+lung+cancer+setback+as+sales+beat+estimates&amp;rft.date=2019-01-24&amp;rft.aulast=Erman&amp;rft.aufirst=Michael&amp;rft_id=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fbristol-myers-opdivo-lung-cancer-172155354.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><cite class="citation web">Waterhouse. <a rel="nofollow" class="external text" href="https://www.ohcare.com/wp-content/uploads/2018/01/Nivolumab-Administered-as-30-Minute-Infusion-Waterhouse-OHC.pdf">"Safety profile of nivolumab administered as 30-minute infusion: Analysis of data from CheckMate 153"</a> <span class="cs1-format">(PDF)</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Safety+profile+of+nivolumab+administered+as+30-minute+infusion%3A+Analysis+of+data+from+CheckMate+153&amp;rft.au=Waterhouse&amp;rft_id=https%3A%2F%2Fwww.ohcare.com%2Fwp-content%2Fuploads%2F2018%2F01%2FNivolumab-Administered-as-30-Minute-Infusion-Waterhouse-OHC.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANivolumab" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
</ol></div></div>
<div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_the_immune_system" style="padding:3px"><table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2" style="text-align:center;"><div class="plainlinks hlist navbar mini"><ul><li class="nv-view"><a href="/wiki/Template:Monoclonals_for_immune_system" title="Template:Monoclonals for immune system"><abbr title="View this template" style="text-align:center;;;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Monoclonals_for_immune_system" title="Template talk:Monoclonals for immune system"><abbr title="Discuss this template" style="text-align:center;;;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">t</abbr></a></li><li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Monoclonals_for_immune_system&amp;action=edit"><abbr title="Edit this template" style="text-align:center;;;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">e</abbr></a></li></ul></div><div id="Monoclonal_antibodies_for_the_immune_system" style="font-size:114%;margin:0 4em"><a href="/wiki/Monoclonal_antibodies" class="mw-redirect" title="Monoclonal antibodies">Monoclonal antibodies</a> for the <a href="/wiki/Immune_system" title="Immune system">immune system</a></div></th></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%"><a href="/wiki/Immune_system" title="Immune system">Immune system</a> ("-l(i[m])-")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human ("-limu-")</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Immunosuppression" title="Immunosuppression">Immunosuppression</a></i>: <a href="/wiki/Abrilumab" title="Abrilumab">Abrilumab</a></li>
<li><a href="/wiki/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li><a href="/wiki/Anifrolumab" title="Anifrolumab">Anifrolumab</a><sup>†</sup></li>
<li><a href="/wiki/Atorolimumab" title="Atorolimumab">Atorolimumab</a></li>
<li><a href="/wiki/Avelumab" title="Avelumab">Avelumab</a></li>
<li><a href="/wiki/Belimumab" title="Belimumab">Belimumab</a></li>
<li><a href="/wiki/Bleselumab" title="Bleselumab">Bleselumab</a></li>
<li><a href="/wiki/Brodalumab" title="Brodalumab">Brodalumab</a></li>
<li><a href="/wiki/Camidanlumab_tesirine" title="Camidanlumab tesirine">Camidanlumab tesirine</a></li>
<li><a href="/wiki/Carlumab" title="Carlumab">Carlumab</a></li>
<li><a href="/wiki/Cemiplimab" title="Cemiplimab">Cemiplimab</a></li>
<li><a href="/wiki/Dupilumab" title="Dupilumab">Dupilumab</a></li>
<li><a href="/wiki/Eldelumab" title="Eldelumab">Eldelumab</a></li>
<li><a href="/wiki/Emapalumab" title="Emapalumab">Emapalumab</a><sup>†</sup></li>
<li><a href="/wiki/Fresolimumab" title="Fresolimumab">Fresolimumab</a></li>
<li><a href="/wiki/Golimumab" title="Golimumab">Golimumab</a></li>
<li><a href="/wiki/Ianalumab" title="Ianalumab">Ianalumab</a><sup>†</sup></li>
<li><a href="/wiki/Lanadelumab" title="Lanadelumab">Lanadelumab</a></li>
<li><a href="/wiki/Lenzilumab" title="Lenzilumab">Lenzilumab</a></li>
<li><a href="/wiki/Lerdelimumab" title="Lerdelimumab">Lerdelimumab</a></li>
<li><a href="/wiki/Lirilumab" title="Lirilumab">Lirilumab</a></li>
<li><a href="/wiki/Mavrilimumab" title="Mavrilimumab">Mavrilimumab</a></li>
<li><a href="/wiki/Metelimumab" title="Metelimumab">Metelimumab</a></li>
<li><a href="/wiki/Morolimumab" title="Morolimumab">Morolimumab</a></li>
<li><a href="/wiki/Namilumab" title="Namilumab">Namilumab</a></li>
<li><a href="/wiki/Oleclumab" title="Oleclumab">Oleclumab</a></li>
<li><a href="/wiki/Oxelumab" title="Oxelumab">Oxelumab</a>§</li>
<li><a href="/wiki/Pamrevlumab" title="Pamrevlumab">Pamrevlumab</a></li>
<li><a href="/wiki/Placulumab" title="Placulumab">Placulumab</a></li>
<li><a href="/wiki/Relatlimab" title="Relatlimab">Relatlimab</a><sup>†</sup></li>
<li><a href="/wiki/Sarilumab" title="Sarilumab">Sarilumab</a></li>
<li><a href="/wiki/Sifalimumab" title="Sifalimumab">Sifalimumab</a></li>
<li><a href="/wiki/Tabalumab" title="Tabalumab">Tabalumab</a></li>
<li><a href="/wiki/Tezepelumab" title="Tezepelumab">Tezepelumab</a><sup>†</sup></li>
<li><a href="/wiki/Ulocuplumab" title="Ulocuplumab">Ulocuplumab</a></li>
<li><a href="/wiki/Varlilumab" title="Varlilumab">Varlilumab</a></li></ul>
<ul><li><i>Immune activation</i>: <a href="/wiki/Ipilimumab" title="Ipilimumab">Ipilimumab</a></li>
<li><a href="/wiki/Atezolizumab" title="Atezolizumab">Atezolizumab</a></li>
<li><a href="/wiki/Durvalumab" title="Durvalumab">Durvalumab</a></li>
<li><a class="mw-selflink selflink">Nivolumab</a></li>
<li><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a></li>
<li><a href="/wiki/Tremelimumab" title="Tremelimumab">Tremelimumab</a><sup>†</sup></li>
<li><a href="/wiki/Urelumab" title="Urelumab">Urelumab</a></li></ul>
<ul><li><i>Other</i>: <a href="/wiki/Bertilimumab" title="Bertilimumab">Bertilimumab</a></li>
<li><a href="/wiki/Zanolimumab" title="Zanolimumab">Zanolimumab</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse ("-limo-")</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Afelimomab" title="Afelimomab">Afelimomab</a></li>
<li><a href="/wiki/Elsilimomab" title="Elsilimomab">Elsilimomab</a></li>
<li><a href="/wiki/Faralimomab" title="Faralimomab">Faralimomab</a></li>
<li><a href="/wiki/Gavilimomab" title="Gavilimomab">Gavilimomab</a></li>
<li><a href="/wiki/Inolimomab" title="Inolimomab">Inolimomab</a></li>
<li><a href="/wiki/Maslimomab" title="Maslimomab">Maslimomab</a></li>
<li><a href="/wiki/Nerelimomab" title="Nerelimomab">Nerelimomab</a></li>
<li><a href="/wiki/Odulimomab" title="Odulimomab">Odulimomab</a></li>
<li><a href="/wiki/Telimomab_aritox" title="Telimomab aritox">Telimomab aritox</a></li>
<li><a href="/wiki/Vepalimomab" title="Vepalimomab">Vepalimomab</a></li>
<li><a href="/wiki/Zolimomab_aritox" title="Zolimomab aritox">Zolimomab aritox</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Chimeric_antibody" class="mw-redirect" title="Chimeric antibody">Chimeric</a> ("-lixi-")</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Andecaliximab" title="Andecaliximab">Andecaliximab</a><sup>†</sup></li>
<li><a href="/wiki/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="/wiki/Clenoliximab" title="Clenoliximab">Clenoliximab</a></li>
<li><a href="/wiki/Galiximab" title="Galiximab">Galiximab</a></li>
<li><a href="/wiki/Gomiliximab" class="mw-redirect" title="Gomiliximab">Gomiliximab</a></li>
<li><a href="/wiki/Infliximab" title="Infliximab">Infliximab</a></li>
<li><a href="/wiki/Keliximab" title="Keliximab">Keliximab</a></li>
<li><a href="/wiki/Lumiliximab" title="Lumiliximab">Lumiliximab</a></li>
<li><a href="/wiki/Priliximab" title="Priliximab">Priliximab</a></li>
<li><a href="/wiki/Teneliximab" title="Teneliximab">Teneliximab</a></li>
<li><a href="/wiki/Vapaliximab" title="Vapaliximab">Vapaliximab</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Humanized_antibody" title="Humanized antibody">Humanized</a> ("-lizu-")</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Immunosuppressive:</i> <a href="/wiki/Aselizumab" title="Aselizumab">Aselizumab</a></li>
<li><a href="/wiki/Apolizumab" title="Apolizumab">Apolizumab</a><sup>§</sup></li>
<li><a href="/wiki/Benralizumab" title="Benralizumab">Benralizumab</a></li>
<li><a href="/wiki/Camrelizumab" title="Camrelizumab">Camrelizumab</a><sup>†</sup></li>
<li><a href="/wiki/Cedelizumab" title="Cedelizumab">Cedelizumab</a></li>
<li><a href="/wiki/Certolizumab_pegol" title="Certolizumab pegol">Certolizumab pegol</a></li>
<li><a href="/wiki/Crizanlizumab" title="Crizanlizumab">Crizanlizumab</a><sup>†</sup></li>
<li><a href="/wiki/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li><a href="/wiki/Eculizumab" title="Eculizumab">Eculizumab</a></li>
<li><a href="/wiki/Efalizumab" title="Efalizumab">Efalizumab</a></li>
<li><a href="/wiki/Epratuzumab" title="Epratuzumab">Epratuzumab</a></li>
<li><a href="/wiki/Erlizumab" title="Erlizumab">Erlizumab</a></li>
<li><a href="/wiki/Etrolizumab" title="Etrolizumab">Etrolizumab</a><sup>†</sup></li>
<li><a href="/wiki/Fontolizumab" title="Fontolizumab">Fontolizumab</a></li>
<li><a href="/wiki/Inebilizumab" title="Inebilizumab">Inebilizumab</a><sup>†</sup></li>
<li><a href="/wiki/Itolizumab" title="Itolizumab">Itolizumab</a></li>
<li><a href="/wiki/Lampalizumab" title="Lampalizumab">Lampalizumab</a><sup>†</sup></li>
<li><a href="/wiki/Letolizumab" title="Letolizumab">Letolizumab</a></li>
<li><a href="/wiki/Ligelizumab" title="Ligelizumab">Ligelizumab</a><sup>†</sup></li>
<li><a href="/wiki/Lulizumab_pegol" title="Lulizumab pegol">Lulizumab pegol</a></li>
<li><a href="/wiki/Mepolizumab" title="Mepolizumab">Mepolizumab</a></li>
<li><a href="/wiki/Mogamulizumab" title="Mogamulizumab">Mogamulizumab</a></li>
<li><a href="/wiki/Natalizumab" title="Natalizumab">Natalizumab</a></li>
<li><a href="/wiki/Ocrelizumab" title="Ocrelizumab">Ocrelizumab</a></li>
<li><a href="/wiki/Omalizumab" title="Omalizumab">Omalizumab</a></li>
<li><a href="/wiki/Ozoralizumab" title="Ozoralizumab">Ozoralizumab</a></li>
<li><a href="/wiki/Pascolizumab" title="Pascolizumab">Pascolizumab</a></li>
<li><a href="/wiki/Pateclizumab" title="Pateclizumab">Pateclizumab</a></li>
<li><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a></li>
<li><a href="/wiki/Pexelizumab" title="Pexelizumab">Pexelizumab</a></li>
<li><a href="/wiki/Pidilizumab" title="Pidilizumab">Pidilizumab</a></li>
<li><a href="/wiki/Plozalizumab" title="Plozalizumab">Plozalizumab</a></li>
<li><a href="/wiki/PRO_140" title="PRO 140">PRO 140</a><sup>†</sup></li>
<li><a href="/wiki/Quilizumab" title="Quilizumab">Quilizumab</a></li>
<li><a href="/wiki/Ravulizumab" title="Ravulizumab">Ravulizumab</a></li>
<li><a href="/wiki/Reslizumab" title="Reslizumab">Reslizumab</a></li>
<li><a href="/wiki/Rontalizumab" title="Rontalizumab">Rontalizumab</a></li>
<li><a href="/wiki/Rovelizumab" title="Rovelizumab">Rovelizumab</a></li>
<li><a href="/wiki/Ruplizumab" title="Ruplizumab">Ruplizumab</a></li>
<li><a href="/wiki/Samalizumab" title="Samalizumab">Samalizumab</a></li>
<li><a href="/wiki/Satralizumab" title="Satralizumab">Satralizumab</a><sup>†</sup></li>
<li><a href="/wiki/Siplizumab" title="Siplizumab">Siplizumab</a></li>
<li><a href="/wiki/Spartalizumab" title="Spartalizumab">Spartalizumab</a><sup>†</sup></li>
<li><a href="/wiki/Talizumab" title="Talizumab">Talizumab</a></li>
<li><a href="/wiki/Teplizumab" title="Teplizumab">Teplizumab</a></li>
<li><a href="/wiki/Tislelizumab" title="Tislelizumab">Tislelizumab</a></li>
<li><a href="/wiki/Tocilizumab" title="Tocilizumab">Tocilizumab</a></li>
<li><a href="/wiki/Toralizumab" title="Toralizumab">Toralizumab</a></li>
<li><a href="/wiki/Tregalizumab" title="Tregalizumab">Tregalizumab</a></li>
<li><a href="/wiki/Vatelizumab" title="Vatelizumab">Vatelizumab</a></li>
<li><a href="/wiki/Vedolizumab" title="Vedolizumab">Vedolizumab</a></li>
<li><a href="/wiki/Visilizumab" title="Visilizumab">Visilizumab</a></li>
<li><a href="/wiki/Vobarilizumab" title="Vobarilizumab">Vobarilizumab</a></li>
<li><a href="/wiki/TGN1412" class="mw-redirect" title="TGN1412">TGN1412</a><sup>§</sup><br /><i>Non-immunosuppressive:</i> <a href="/wiki/Ibalizumab" title="Ibalizumab">Ibalizumab</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chimeric + humanized<br />("-lixizu-")</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Otelixizumab" title="Otelixizumab">Otelixizumab</a></li>
<li><a href="/wiki/Sutimlimab" title="Sutimlimab">Sutimlimab</a><sup>†</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%"><a href="/wiki/Interleukin" title="Interleukin">Interleukin</a> ("-k(i[n])-")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human ("-kinu-")</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Bermekimab" title="Bermekimab">Bermekimab</a></li>
<li><a href="/wiki/Brazikumab" title="Brazikumab">Brazikumab</a></li>
<li><a href="/wiki/Briakinumab" title="Briakinumab">Briakinumab</a></li>
<li><a href="/wiki/Canakinumab" title="Canakinumab">Canakinumab</a></li>
<li><a href="/wiki/Fezakinumab" title="Fezakinumab">Fezakinumab</a></li>
<li><a href="/wiki/Fletikumab" title="Fletikumab">Fletikumab</a></li>
<li><a href="/wiki/Guselkumab" title="Guselkumab">Guselkumab</a></li>
<li><a href="/wiki/Secukinumab" title="Secukinumab">Secukinumab</a></li>
<li><a href="/wiki/Sirukumab" title="Sirukumab">Sirukumab</a></li>
<li><a href="/wiki/Tralokinumab" title="Tralokinumab">Tralokinumab</a><sup>†</sup></li>
<li><a href="/wiki/Ustekinumab" title="Ustekinumab">Ustekinumab</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Humanized ("-kizu-", "-kinzu-")</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Anrukinzumab" title="Anrukinzumab">Anrukinzumab</a></li>
<li><a href="/wiki/Bimekizumab" title="Bimekizumab">Bimekizumab</a><sup>†</sup></li>
<li><a href="/wiki/Clazakizumab" title="Clazakizumab">Clazakizumab</a></li>
<li><a href="/wiki/Gevokizumab" title="Gevokizumab">Gevokizumab</a></li>
<li><a href="/wiki/Ixekizumab" title="Ixekizumab">Ixekizumab</a></li>
<li><a href="/wiki/Mirikizumab" title="Mirikizumab">Mirikizumab</a><sup>†</sup></li>
<li><a href="/wiki/Lebrikizumab" title="Lebrikizumab">Lebrikizumab</a></li>
<li><a href="/wiki/Olokizumab" title="Olokizumab">Olokizumab</a><sup>†</sup></li>
<li><a href="/wiki/Perakizumab" title="Perakizumab">Perakizumab</a></li>
<li><a href="/wiki/Risankizumab" title="Risankizumab">Risankizumab</a><sup>†</sup></li>
<li><a href="/wiki/Tildrakizumab" title="Tildrakizumab">Tildrakizumab</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Veterinary ("-kivet-")</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Lokivetmab" title="Lokivetmab">Lokivetmab</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Inflammatory <a href="/wiki/Lesion" title="Lesion">lesions</a> ("-les-")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="Mouse_(&amp;quot;-leso-&amp;quot;)" scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse ("-leso-")</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Besilesomab" title="Besilesomab">Besilesomab</a></li>
<li><a href="/wiki/Technetium_(99mTc)_fanolesomab" title="Technetium (99mTc) fanolesomab">Fanolesomab</a><sup>‡</sup></li>
<li><a href="/wiki/Lemalesomab" title="Lemalesomab">Lemalesomab</a></li>
<li><a href="/wiki/Technetium_(99mTc)_sulesomab" title="Technetium (99mTc) sulesomab">Sulesomab</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="text-align:center;;background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup><a href="/wiki/WHO_Model_List_of_Essential_Medicines" title="WHO Model List of Essential Medicines">WHO-EM</a></li>
<li><sup>‡</sup><a href="/wiki/List_of_withdrawn_drugs" title="List of withdrawn drugs">Withdrawn</a> from market</li>
<li><a href="/wiki/Clinical_trial" title="Clinical trial">Clinical trials</a>:
<ul><li><sup>†</sup><a href="/wiki/Phases_of_clinical_research#Phase_III" title="Phases of clinical research">Phase III</a></li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>

<!-- 
NewPP limit report
Parsed by mw1321
Cached time: 20190127201014
Cache expiry: 2073600
Dynamic content: false
CPU time usage: 0.632 seconds
Real time usage: 0.811 seconds
Preprocessor visited node count: 4736/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 99245/2097152 bytes
Template argument size: 1811/2097152 bytes
Highest expansion depth: 15/40
Expensive parser function count: 4/500
Unstrip recursion depth: 1/20
Unstrip post‐expand size: 75038/5000000 bytes
Number of Wikibase entities loaded: 4/400
Lua time usage: 0.292/10.000 seconds
Lua memory usage: 4.81 MB/50 MB
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  699.791      1 -total
 51.02%  356.999      1 Template:Drugbox
 40.84%  285.775      1 Template:Reflist
 35.61%  249.211      1 Template:Infobox
 28.60%  200.170      9 Template:Cite_journal
 11.35%   79.437     16 Template:Unbulleted_list
  4.96%   34.702      9 Template:Cite_web
  4.63%   32.373      1 Template:Infobox_drug/chemical_formula
  3.72%   26.059      4 Template:Navbox
  3.59%   25.115      1 Template:Monoclonals_for_immune_system
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:35007537-0!canonical and timestamp 20190127201013 and revision id 880151338
 -->
</div><noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Nivolumab&amp;oldid=880151338">https://en.wikipedia.org/w/index.php?title=Nivolumab&amp;oldid=880151338</a>"					</div>
				<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Bristol-Myers_Squibb" title="Category:Bristol-Myers Squibb">Bristol-Myers Squibb</a></li><li><a href="/wiki/Category:Monoclonal_antibodies" title="Category:Monoclonal antibodies">Monoclonal antibodies</a></li><li><a href="/wiki/Category:Antineoplastic_drugs" title="Category:Antineoplastic drugs">Antineoplastic drugs</a></li><li><a href="/wiki/Category:Breakthrough_therapy" title="Category:Breakthrough therapy">Breakthrough therapy</a></li><li><a href="/wiki/Category:Monoclonal_antibodies_for_tumors" title="Category:Monoclonal antibodies for tumors">Monoclonal antibodies for tumors</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Chemicals_that_do_not_have_a_ChemSpider_ID_assigned" title="Category:Chemicals that do not have a ChemSpider ID assigned">Chemicals that do not have a ChemSpider ID assigned</a></li><li><a href="/wiki/Category:Articles_without_EBI_source" title="Category:Articles without EBI source">Articles without EBI source</a></li><li><a href="/wiki/Category:Chemical_pages_without_DrugBank_identifier" title="Category:Chemical pages without DrugBank identifier">Chemical pages without DrugBank identifier</a></li><li><a href="/wiki/Category:Articles_without_InChI_source" title="Category:Articles without InChI source">Articles without InChI source</a></li><li><a href="/wiki/Category:Articles_without_UNII_source" title="Category:Articles without UNII source">Articles without UNII source</a></li><li><a href="/wiki/Category:Drugs_with_no_legal_status" title="Category:Drugs with no legal status">Drugs with no legal status</a></li><li><a href="/wiki/Category:Drug_has_EMA_link" title="Category:Drug has EMA link">Drug has EMA link</a></li><li><a href="/wiki/Category:Articles_containing_unverified_chemical_infoboxes" title="Category:Articles containing unverified chemical infoboxes">Articles containing unverified chemical infoboxes</a></li><li><a href="/wiki/Category:Drugs_that_are_a_monoclonal_antibody" title="Category:Drugs that are a monoclonal antibody">Drugs that are a monoclonal antibody</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>
			<div id="mw-head">
									<div id="p-personal" role="navigation" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-anonuserpage">Not logged in</li><li id="pt-anontalk"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n">Talk</a></li><li id="pt-anoncontribs"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y">Contributions</a></li><li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Nivolumab" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Nivolumab" title="You&#039;re encouraged to log in; however, it&#039;s not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
							<li id="ca-nstab-main" class="selected"><span><a href="/wiki/Nivolumab" title="View the content page [c]" accesskey="c">Article</a></span></li><li id="ca-talk"><span><a href="/wiki/Talk:Nivolumab" rel="discussion" title="Discussion about the content page [t]" accesskey="t">Talk</a></span></li>						</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<input type="checkbox" class="vectorMenuCheckbox" aria-labelledby="p-variants-label" />
						<h3 id="p-variants-label">
							<span>Variants</span>
						</h3>
						<ul class="menu">
													</ul>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
							<li id="ca-view" class="collapsible selected"><span><a href="/wiki/Nivolumab">Read</a></span></li><li id="ca-edit" class="collapsible"><span><a href="/w/index.php?title=Nivolumab&amp;action=edit" title="Edit this page [e]" accesskey="e">Edit</a></span></li><li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Nivolumab&amp;action=history" title="Past revisions of this page [h]" accesskey="h">View history</a></span></li>						</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<input type="checkbox" class="vectorMenuCheckbox" aria-labelledby="p-cactions-label" />
						<h3 id="p-cactions-label"><span>More</span></h3>
						<ul class="menu">
													</ul>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>
						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
								<input type="search" name="search" placeholder="Search Wikipedia" title="Search Wikipedia [f]" accesskey="f" id="searchInput"/><input type="hidden" value="Special:Search" name="title"/><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton"/><input type="submit" name="go" value="Go" title="Go to a page with this exact name if it exists" id="searchButton" class="searchButton"/>							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page" title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id="p-navigation" aria-labelledby="p-navigation-label">
			<h3 id="p-navigation-label">Navigation</h3>
			<div class="body">
								<ul>
					<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikipedia store">Wikipedia store</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-interaction" aria-labelledby="p-interaction-label">
			<h3 id="p-interaction-label">Interaction</h3>
			<div class="body">
								<ul>
					<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact page</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-tb" aria-labelledby="p-tb-label">
			<h3 id="p-tb-label">Tools</h3>
			<div class="body">
								<ul>
					<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Nivolumab" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Nivolumab" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Nivolumab&amp;oldid=880151338" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Nivolumab&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q7041828" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Nivolumab&amp;id=880151338" title="Information on how to cite this page">Cite this page</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-coll-print_export" aria-labelledby="p-coll-print_export-label">
			<h3 id="p-coll-print_export-label">Print/export</h3>
			<div class="body">
								<ul>
					<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Nivolumab">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:ElectronPdf&amp;page=Nivolumab&amp;action=show-download-screen">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Nivolumab&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-lang" aria-labelledby="p-lang-label">
			<h3 id="p-lang-label">Languages</h3>
			<div class="body">
								<ul>
					<li class="interlanguage-link interwiki-ar"><a href="https://ar.wikipedia.org/wiki/%D9%86%D9%8A%D9%81%D9%88%D9%84%D9%88%D9%85%D8%A7%D8%A8" title="نيفولوماب – Arabic" lang="ar" hreflang="ar" class="interlanguage-link-target">العربية</a></li><li class="interlanguage-link interwiki-de"><a href="https://de.wikipedia.org/wiki/Nivolumab" title="Nivolumab – German" lang="de" hreflang="de" class="interlanguage-link-target">Deutsch</a></li><li class="interlanguage-link interwiki-el"><a href="https://el.wikipedia.org/wiki/Nivolumab" title="Nivolumab – Greek" lang="el" hreflang="el" class="interlanguage-link-target">Ελληνικά</a></li><li class="interlanguage-link interwiki-es"><a href="https://es.wikipedia.org/wiki/Nivolumab" title="Nivolumab – Spanish" lang="es" hreflang="es" class="interlanguage-link-target">Español</a></li><li class="interlanguage-link interwiki-fr"><a href="https://fr.wikipedia.org/wiki/Nivolumab" title="Nivolumab – French" lang="fr" hreflang="fr" class="interlanguage-link-target">Français</a></li><li class="interlanguage-link interwiki-ko"><a href="https://ko.wikipedia.org/wiki/%EC%98%B5%EB%94%94%EB%B3%B4" title="옵디보 – Korean" lang="ko" hreflang="ko" class="interlanguage-link-target">한국어</a></li><li class="interlanguage-link interwiki-ja"><a href="https://ja.wikipedia.org/wiki/%E3%83%8B%E3%83%9C%E3%83%AB%E3%83%9E%E3%83%96" title="ニボルマブ – Japanese" lang="ja" hreflang="ja" class="interlanguage-link-target">日本語</a></li><li class="interlanguage-link interwiki-no"><a href="https://no.wikipedia.org/wiki/Nivolumab" title="Nivolumab – Norwegian" lang="no" hreflang="no" class="interlanguage-link-target">Norsk</a></li><li class="interlanguage-link interwiki-pl"><a href="https://pl.wikipedia.org/wiki/Niwolumab" title="Niwolumab – Polish" lang="pl" hreflang="pl" class="interlanguage-link-target">Polski</a></li>				</ul>
				<div class="after-portlet after-portlet-lang"><span class="wb-langlinks-edit wb-langlinks-link"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q7041828#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
				<div id="footer" role="contentinfo">
						<ul id="footer-info">
								<li id="footer-info-lastmod"> This page was last edited on 25 January 2019, at 17:56<span class="anonymous-show">&#160;(UTC)</span>.</li>
								<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//foundation.wikimedia.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//foundation.wikimedia.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
							</ul>
						<ul id="footer-places">
								<li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Privacy_policy" class="extiw" title="wmf:Privacy policy">Privacy policy</a></li>
								<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
								<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
								<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
								<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
								<li id="footer-places-cookiestatement"><a href="https://foundation.wikimedia.org/wiki/Cookie_statement">Cookie statement</a></li>
								<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Nivolumab&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
							</ul>
										<ul id="footer-icons" class="noprint">
										<li id="footer-copyrightico">
						<a href="https://wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>					</li>
										<li id="footer-poweredbyico">
						<a href="//www.mediawiki.org/"><img src="/static/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/static/images/poweredby_mediawiki_132x47.png 1.5x, /static/images/poweredby_mediawiki_176x62.png 2x" width="88" height="31"/></a>					</li>
									</ul>
						<div style="clear: both;"></div>
		</div>
		
<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.632","walltime":"0.811","ppvisitednodes":{"value":4736,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":99245,"limit":2097152},"templateargumentsize":{"value":1811,"limit":2097152},"expansiondepth":{"value":15,"limit":40},"expensivefunctioncount":{"value":4,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":75038,"limit":5000000},"entityaccesscount":{"value":4,"limit":400},"timingprofile":["100.00%  699.791      1 -total"," 51.02%  356.999      1 Template:Drugbox"," 40.84%  285.775      1 Template:Reflist"," 35.61%  249.211      1 Template:Infobox"," 28.60%  200.170      9 Template:Cite_journal"," 11.35%   79.437     16 Template:Unbulleted_list","  4.96%   34.702      9 Template:Cite_web","  4.63%   32.373      1 Template:Infobox_drug/chemical_formula","  3.72%   26.059      4 Template:Navbox","  3.59%   25.115      1 Template:Monoclonals_for_immune_system"]},"scribunto":{"limitreport-timeusage":{"value":"0.292","limit":"10.000"},"limitreport-memusage":{"value":5045477,"limit":52428800}},"cachereport":{"origin":"mw1321","timestamp":"20190127201014","ttl":2073600,"transientcontent":false}}});});</script>
<script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"Nivolumab","url":"https:\/\/en.wikipedia.org\/wiki\/Nivolumab","sameAs":"http:\/\/www.wikidata.org\/entity\/Q7041828","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q7041828","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2012-03-08T19:20:00Z","dateModified":"2019-01-25T17:56:28Z","image":"https:\/\/upload.wikimedia.org\/wikipedia\/commons\/1\/1e\/Nivolumab_5GGR.png","headline":"pharmaceutical drug"}</script>
<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgBackendResponseTime":102,"wgHostname":"mw1245"});});</script>
	</body>
</html>
